SG11201706872SA - Combination of a pd-1 antagonist and eribulin for treating cancer - Google Patents
Combination of a pd-1 antagonist and eribulin for treating cancerInfo
- Publication number
- SG11201706872SA SG11201706872SA SG11201706872SA SG11201706872SA SG11201706872SA SG 11201706872S A SG11201706872S A SG 11201706872SA SG 11201706872S A SG11201706872S A SG 11201706872SA SG 11201706872S A SG11201706872S A SG 11201706872SA SG 11201706872S A SG11201706872S A SG 11201706872SA
- Authority
- SG
- Singapore
- Prior art keywords
- eribulin
- antagonist
- combination
- treating cancer
- cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 229940124060 PD-1 antagonist Drugs 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- UFNVPOGXISZXJD-XJPMSQCNSA-N eribulin Chemical compound C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 UFNVPOGXISZXJD-XJPMSQCNSA-N 0.000 title 1
- 229960003649 eribulin Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562128373P | 2015-03-04 | 2015-03-04 | |
| US201562264068P | 2015-12-07 | 2015-12-07 | |
| PCT/US2016/020734 WO2016141209A1 (en) | 2015-03-04 | 2016-03-03 | Combination of a pd-1 antagonist and eribulin for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201706872SA true SG11201706872SA (en) | 2017-09-28 |
Family
ID=55586425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201706872SA SG11201706872SA (en) | 2015-03-04 | 2016-03-03 | Combination of a pd-1 antagonist and eribulin for treating cancer |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10945990B2 (enExample) |
| EP (1) | EP3265122B1 (enExample) |
| JP (1) | JP6951248B2 (enExample) |
| KR (1) | KR20170122810A (enExample) |
| CN (1) | CN107810013B (enExample) |
| AU (1) | AU2016226157B2 (enExample) |
| BR (1) | BR112017018872A2 (enExample) |
| CA (1) | CA2978311A1 (enExample) |
| IL (1) | IL254133B (enExample) |
| MX (1) | MX386547B (enExample) |
| RU (1) | RU2737216C2 (enExample) |
| SG (1) | SG11201706872SA (enExample) |
| WO (1) | WO2016141209A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE046436T2 (hu) | 2004-06-03 | 2020-02-28 | Eisai R&D Man Co Ltd | Köztitermékek halikondrin B elõállításához |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| MA33127B1 (fr) | 2009-03-30 | 2012-03-01 | Eisai R&D Man Co Ltd | Composition liposomique |
| WO2015109391A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| EP3265122B1 (en) | 2015-03-04 | 2022-05-04 | Merck Sharp & Dohme Corp. | Combination of pembrolizumab and eribulin for treating triple-negative breast cancer |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| NZ738406A (en) * | 2015-06-11 | 2023-04-28 | Bionomics Ltd | Pharmaceutical combination of a tubulin polymerization inhibitor with an inhibitor of pd-l1, pd-1, or ctla-4 and uses and compositions thereof |
| US10513558B2 (en) | 2015-07-13 | 2019-12-24 | Cytomx Therapeutics, Inc. | Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof |
| US12029724B2 (en) | 2016-04-28 | 2024-07-09 | Eisai R&D Management Co., Ltd. | Method for inhibiting tumor growth |
| CN110072552A (zh) * | 2016-10-14 | 2019-07-30 | 默沙东公司 | 用于治疗尿路上皮癌的pd-1拮抗剂和艾立布林的组合 |
| WO2018075740A1 (en) * | 2016-10-21 | 2018-04-26 | Merck Sharp & Dohme Corp. | Treating cancer with a combination of pd-1 antagonist and an il-27 antagonist |
| EP3654967A4 (en) * | 2017-07-21 | 2021-04-21 | Eisai R&D Management Co., Ltd. | USE OF EIBULIN AND CYCLINE-DEPENDENT KINASE INHIBITORS IN THE TREATMENT OF CANCER |
| WO2019097073A1 (en) | 2017-11-20 | 2019-05-23 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
| EP3806846A1 (en) * | 2018-06-15 | 2021-04-21 | Board of Regents, The University of Texas System | Methods of treating and preventing breast cancer with s-equol |
| WO2019240872A1 (en) | 2018-06-15 | 2019-12-19 | The Board Of Regents Of The University Of Texas System | Methods of treating and preventing melanoma with s-equol |
| US12036204B2 (en) | 2019-07-26 | 2024-07-16 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| US11083705B2 (en) * | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
| WO2021084441A2 (en) * | 2019-10-28 | 2021-05-06 | Enzychem Lifesciences Corporation | Methods and compositions for treatment of cancer |
| WO2025049528A1 (en) * | 2023-08-29 | 2025-03-06 | Cullinan Amber Corp. | Combination therapies for cancer |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DK1087960T3 (da) * | 1998-06-17 | 2011-06-14 | Eisai R&D Man Co Ltd | Makrocykliske analoger og fremgangsmåder til deres anvendelse og fremstilling |
| US8097648B2 (en) | 1998-06-17 | 2012-01-17 | Eisai R&D Management Co., Ltd. | Methods and compositions for use in treating cancer |
| WO2000032634A1 (en) | 1998-12-01 | 2000-06-08 | Protein Design Labs, Inc. | Humanized antibodies to gamma-interferon |
| US7595048B2 (en) | 2002-07-03 | 2009-09-29 | Ono Pharmaceutical Co., Ltd. | Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1 |
| BR0316880A (pt) | 2002-12-23 | 2005-10-25 | Wyeth Corp | Anticorpos contra pd-1 e usos dos mesmos |
| WO2004072286A1 (ja) | 2003-01-23 | 2004-08-26 | Ono Pharmaceutical Co., Ltd. | ヒトｐｄ−１に対し特異性を有する物質 |
| HUE046436T2 (hu) | 2004-06-03 | 2020-02-28 | Eisai R&D Man Co Ltd | Köztitermékek halikondrin B elõállításához |
| EP2439273B1 (en) | 2005-05-09 | 2019-02-27 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| KR101888321B1 (ko) | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| US8093410B2 (en) | 2007-10-03 | 2012-01-10 | Eisai R&D Management Co., Ltd. | Intermediates and methods for the synthesis of halichondrin B analogs |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| MX2011002250A (es) | 2008-08-25 | 2011-08-17 | Amplimmune Inc | Antagonistas de muerte celular programada-1 y métodos de uso de los mismos. |
| MX2011003195A (es) | 2008-09-26 | 2011-08-12 | Dana Farber Cancer Inst Inc | Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos. |
| US8217149B2 (en) | 2008-12-09 | 2012-07-10 | Genentech, Inc. | Anti-PD-L1 antibodies, compositions and articles of manufacture |
| JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害 |
| RU2579511C2 (ru) | 2010-01-26 | 2016-04-10 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Производные фуро[3,2-в]пирана, применимые в синтезе аналогов |
| WO2012119077A1 (en) | 2011-03-02 | 2012-09-07 | Morphotek Inc. | Co -administration of eribulin and farletuzumab for the treatment of breast cancer |
| CA2828959A1 (en) * | 2011-03-18 | 2012-09-27 | Eisai R&D Management Co., Ltd. | Methods and compositions for predicting response to eribulin |
| AU2012236479B2 (en) | 2011-03-31 | 2016-10-20 | Merck Sharp & Dohme Llc | Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments |
| MY193562A (en) | 2011-08-01 | 2022-10-19 | Genentech Inc | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
| RU2689977C2 (ru) * | 2012-12-04 | 2019-05-30 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Применение эрибулина для лечения рака молочной железы |
| AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| US20160067337A1 (en) | 2013-03-14 | 2016-03-10 | Bristol-Myers Squibb Company | Combination of dr5 agonist and anti-pd-1 antagonist and methods of use |
| JP6720075B2 (ja) * | 2013-05-31 | 2020-07-08 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 癌のための併用療法 |
| RU2015156221A (ru) | 2013-06-11 | 2017-07-17 | Новартис Аг | Фармацевтические комбинация ингибитора pi3k и средства, дестабилизирующего микротрубочки |
| JP6404242B2 (ja) * | 2013-06-26 | 2018-10-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | がんの治療のための併用療法としてのエリブリンおよびレンバチニブの使用 |
| US9457019B2 (en) | 2013-11-07 | 2016-10-04 | Deciphera Pharmaceuticals, Llc | Methods for inhibiting tie-2 kinase useful in the treatment of cancer |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JP2017507155A (ja) | 2014-03-05 | 2017-03-16 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｐｄ−１抗体と他の抗癌剤の組合せを使用する腎癌の処置 |
| EP3148526B1 (en) | 2014-05-28 | 2021-01-06 | Eisai R&D Management Co., Ltd. | Use of eribulin in the treatment of cancer |
| EP3265122B1 (en) | 2015-03-04 | 2022-05-04 | Merck Sharp & Dohme Corp. | Combination of pembrolizumab and eribulin for treating triple-negative breast cancer |
-
2016
- 2016-03-03 EP EP16710891.9A patent/EP3265122B1/en not_active Revoked
- 2016-03-03 MX MX2017011206A patent/MX386547B/es unknown
- 2016-03-03 BR BR112017018872A patent/BR112017018872A2/pt not_active IP Right Cessation
- 2016-03-03 US US15/554,540 patent/US10945990B2/en active Active
- 2016-03-03 JP JP2017546075A patent/JP6951248B2/ja active Active
- 2016-03-03 CN CN201680025588.3A patent/CN107810013B/zh not_active Expired - Fee Related
- 2016-03-03 SG SG11201706872SA patent/SG11201706872SA/en unknown
- 2016-03-03 RU RU2017132877A patent/RU2737216C2/ru active
- 2016-03-03 CA CA2978311A patent/CA2978311A1/en not_active Abandoned
- 2016-03-03 WO PCT/US2016/020734 patent/WO2016141209A1/en not_active Ceased
- 2016-03-03 KR KR1020177027617A patent/KR20170122810A/ko not_active Ceased
- 2016-03-03 AU AU2016226157A patent/AU2016226157B2/en not_active Ceased
-
2017
- 2017-08-24 IL IL254133A patent/IL254133B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX386547B (es) | 2025-03-19 |
| RU2017132877A (ru) | 2019-04-05 |
| CN107810013A (zh) | 2018-03-16 |
| US10945990B2 (en) | 2021-03-16 |
| EP3265122B1 (en) | 2022-05-04 |
| JP6951248B2 (ja) | 2021-10-20 |
| CA2978311A1 (en) | 2016-09-09 |
| CN107810013B (zh) | 2021-04-02 |
| JP2018508516A (ja) | 2018-03-29 |
| IL254133B (en) | 2021-09-30 |
| MX2017011206A (es) | 2018-05-17 |
| RU2737216C2 (ru) | 2020-11-26 |
| EP3265122A1 (en) | 2018-01-10 |
| IL254133A0 (en) | 2017-10-31 |
| KR20170122810A (ko) | 2017-11-06 |
| WO2016141209A1 (en) | 2016-09-09 |
| RU2017132877A3 (enExample) | 2019-08-29 |
| US20180071247A1 (en) | 2018-03-15 |
| AU2016226157B2 (en) | 2022-01-27 |
| BR112017018872A2 (pt) | 2018-05-29 |
| AU2016226157A1 (en) | 2017-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL254133B (en) | Combination of pd-1 antagonist and eribulin for cancer treatment | |
| IL246760A0 (en) | Combination of pd-1 antagonist and vegfr inhibitor for cancer treatment | |
| IL247102B1 (en) | Combination of pd-1 antagonist and ido1 inhibitor for cancer treatment | |
| IL304820A (en) | Preparations and methods for the treatment of cancer | |
| IL276314A (en) | Preparations for the treatment of cancer using PD-1 axis binding antagonists and MEK inhibitors | |
| IL250187A0 (en) | Combination of a pd-1 antagonist and a listeria-based vaccine for the treatment of prostate cancer | |
| IL263178A (en) | Fidi-1 / Fidi-AL1 inhibitors for cancer treatment | |
| IL254131A0 (en) | Fidi-1 / Fidi-AL1 inhibitors for cancer treatment | |
| IL252610A0 (en) | Methods and preparations for the treatment of cancer | |
| IL249658A0 (en) | Methods of treating cancer using tigit inhibitors and anticancer agents | |
| IL265917A (en) | Combination of a pd-1 antagonist and eribulin for treating urothelial cancer | |
| WO2016154412A9 (en) | Combination of a pd-1 antagonist and a listeria based vaccine for treating pancreatic cancer | |
| PT3200815T (pt) | Métodos e composições para o tratamento de cancro | |
| IL256523A (en) | Compositions and methods for treating cancer | |
| SG11201802952TA (en) | Compounds for treatment of cancer and epigenetics | |
| IL255638A (en) | Compositions and methods for treating cancer | |
| IL253905A0 (en) | Combination of hsp90 inhibitors and pd-1 inhibitors for cancer treatment | |
| IL256763A (en) | Compositions and methods for treating cancer |